enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Pertuzumab - Wikipedia

   en.wikipedia.org/wiki/Pertuzumab

   Pertuzumab is administered as an intravenous infusion in combination with trastuzumab and docetaxel as a first line treatment for HER2-positive metastatic breast cancer. [4] [3] It is also used in the same combination as a neoadjuvant (given to reduce the size of a tumor, prior to surgery or radiation) for HER2-positive early breast cancer; as of 2016 this use had not been shown to increase ...

3. FDA Advisory Committee Recommends Accelerated Approval of ...

   www.aol.com/news/2013-09-12-fda-advisory...

   FDA Advisory Committee Recommends Accelerated Approval of Genentech's Perjeta for Neoadjuvant Use in HER2-Positive Early Stage Breast Cancer The FDA Will Make a Final Decision by October 31 The ...

4. FDA Grants Genentech's Perjeta Accelerated Approval for Use ...

   www.aol.com/news/2013-09-30-fda-grants-genen...

   For premium support please call: 800-290-4726 more ways to reach us

5. Trastuzumab deruxtecan - Wikipedia

   en.wikipedia.org/wiki/Trastuzumab_deruxtecan

   Trastuzumab deruxtecan was approved for medical use in the United States in December 2019, [12] in Japan in March 2020, [14] in the European Union in January 2021, [8] [10] and in Australia in October 2021. [1] It is the first approved therapy by the US Food and Drug Administration (FDA) targeted to people with the HER2-low breast cancer ...

6. FDA Grants Genentech's Perjeta Regimen Priority Review for ...

   www.aol.com/2013/07/02/fda-grants-genentechs...

   For premium support please call: 800-290-4726 more ways to reach us

7. Ofatumumab - Wikipedia

   en.wikipedia.org/wiki/Ofatumumab

   Ofatumumab is a fully human monoclonal antibody to CD20, which appears to provide rapid B-cell depletion. [13] Under the brand name Kesimpta, it is approved for the treatment of multiple sclerosis in the United States as well as in the European Union and other regions.

8. Roche's SC Formulation of Perjeta-Herceptin Combo Gets FDA Nod

   www.aol.com/news/roches-sc-formulation-perjeta...

   For premium support please call: 800-290-4726 more ways to reach us

9. Idecabtagene vicleucel - Wikipedia

   en.wikipedia.org/wiki/Idecabtagene_vicleucel

   Idecabtagene vicleucel was approved for medical use in the United States in March 2021. [4] [7] It is the first cell-based gene therapy approved by the US Food and Drug Administration (FDA) for the treatment of multiple myeloma. [4] [7] It was approved for medical use in the European Union in August 2021. [5] [9]